Skip to main content

Qualified laboratory research use only. Not for human or veterinary use, consumption, administration, compounding, diagnosis, or treatment.

RESEARCH USE ONLY
BPC-157 Vespera catalog photography

Research material profile

BPC-157

Synthetic pentadecapeptide

BPC-157 is a 15-amino-acid research peptide. Published work has mostly used isolated cells, tissues, and animal models to study vascular signaling and repair-related processes.

Identity shorthand
GEPPPGKPADDAGLV
Evidence map
Preclinical-dominant evidence
Public page scope
Identity and literature context; no purchase offer
Commerce accessQualified laboratory buyers only

Pricing, availability, ordering, cart, and checkout remain inside the reviewed qualified-access portal.

Qualified catalog access

Plain-language identity

What BPC-157 is

BPC-157 is a 15-amino-acid research peptide. Published work has mostly used isolated cells, tissues, and animal models to study vascular signaling and repair-related processes.

Research class
Synthetic pentadecapeptide
Sequence / identity shorthand
GEPPPGKPADDAGLV
Evidence map
Preclinical-dominant evidence
Identity boundary

The short name “BPC-157” does not establish salt form, counter-ion, purity, or peptide-related impurities. Those details belong in a lot-specific specification or analytical record.

What researchers examine

  • Endothelial signaling and nitric-oxide-associated vascular responses in cell, tissue, and animal models.
  • VEGFR2-associated signaling, endothelial migration, and tube-formation assays.
  • How peptide identity, impurities, and experimental system affect reproducibility across studies.

How to read the evidence

  • A 2017 study reported VEGFR2-associated effects in endothelial assays and a rat hind-limb ischemia model.
  • A 2026 ex vivo study used discarded human internal mammary artery rings; it was a tissue experiment, not a clinical safety or efficacy trial.
  • Model-specific findings should be described as observations in those systems, not as established outcomes in people or animals.

What this evidence does not establish

  • The public literature does not establish this Vespera catalog material as safe, effective, sterile, or suitable for administration.
  • FDA identifies limited safety information and peptide-impurity and characterization concerns for compounded drugs containing BPC-157.
  • A research-use label is meaningful only when buyer qualification, access control, fulfillment review, and actual use remain research-only.

Documentation checklist

  • Match the exact product name, selected strength, SKU, and lot or batch identifier.
  • Review the stated analytical method, result, sample identity, and report date together.
  • Do not treat a purity percentage alone as proof of sequence identity, quantity, sterility, or suitability for a particular experiment.

Primary and official sources

Links are provided for source review. A citation is not an endorsement of nonresearch use.

  1. Liu et al. — VEGFR2 activation and up-regulation in BPC-157 models (2017)Endothelial assays, chick membrane assay, and rat model.
  2. Yildirim et al. — vasorelaxant effects in human arterial rings (2026)Ex vivo human tissue study; not a clinical trial.
  3. FDA — bulk substances that may present significant safety risksRegulatory context for compounded drugs containing BPC-157.
Research use only. This profile contains identity and literature context only. It provides no dosing, administration, reconstitution, diagnosis, treatment, or personal-use guidance.